Expansion of Cytomegalovirus pp65 and IE-1 Specific Cytotoxic T Lymphocytes for Cytomegalovirus-Specific Immunotherapy Following Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 10, 2008, Pages 1156-1162

  Bao, Lei ^a   Dunham, Kimberly ^a   Stamer, Mindy ^a   Mulieri, Kevin M ^a   Lucas, Kenneth G ^a  

^a PENN STATE CHILDREN S HOSPITAL   (United States)

Author keywords

Cytomegalovirus; Cytotoxic T cells; Immunotherapy; Stem cell transplant

Indexed keywords

CIDOFOVIR; CYTOMEGALOVIRUS ANTIGEN PP65; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 1; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG COST; DRUG MECHANISM; EFFECTOR CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAINTENANCE THERAPY; NONHUMAN; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VIRUS REACTIVATION;

ANTIGENS, VIRAL; CELL PROLIFERATION; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PHOSPHOPROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 51649111667     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.07.014     Document Type: Article

References (25)

1. Salzberger B., Bowden R.A., Hackman R.C., et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 90 (1997) 2502-2508
2. Battiwalla M., Wu Y., Bajwa R.P., et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 13 (2007) 765-770
3. Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257 (1992) 238-241
4. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 (2002) 3916-3922
5. Peggs K.S., Verfuerth S., Pizzey A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362 (2003) 1375-1377
6. + T cell responses against a cytomegalovirus antigen. J Immunol 165 (2000) 4105-4111
7. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12 (2006) 1160-1166
8. Lucas K.G., Sun Q., Burton R.L., et al. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther 11 (2000) 1453-1463
9. Thomson K., Julie M., Pang K., et al. Direct isolation of donor-derived antigen-specific T cells and their adoptive transfer for treatment or prophylaxis of CMV infection following allogeneic transplantation. Blood 108 (2006) 177a
10. Wills M.R., Carmichael A.J., Mynard K., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70 (1996) 7569-7579
11. Khan N., Best D., Bruton R., et al. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 178 (2007) 4455-4465
12. + T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 172 (2004) 2256-2264
13. Jacobson M.A., Sinclair E., Bredt B., et al. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 35 (2006) 332-337
14. Schultze J.L., Michalak S., Seamon M.J., et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100 (1997) 2757-2765
15. Bao L., Sun Q., and Lucas K.G. Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother 30 (2007) 557-561
16. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118 (1993) 173-178
17. Riddell S.R., and Greenberg P.D. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 13 (1995) 545-586
18. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996) 4063-4071
19. Winston D.J., Ho W.G., Bartoni K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 118 (1993) 179-184
20. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71 (2006) 154-163
21. + T cells dominate the memory compartments of exposed subjects. J Exp Med 202 (2005) 673-685
22. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333 (1995) 1038-1044
23. Bunde T., Kirchner A., Hoffmeister B., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201 (2005) 1031-1036
24. Lacey S.F., La Rosa C., Zhou W., et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem cell transplant and solid organ transplant recipients. J Infect Dis 194 (2006) 1410-1421
25. Peggs K.S., and Mackinnon S. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Hum Immunol 65 (2004) 550-557